Free Trial

scPharmaceuticals (SCPH) Stock Price, News & Analysis

scPharmaceuticals logo
$4.38 -0.09 (-2.01%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.38 0.00 (0.00%)
As of 07/11/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About scPharmaceuticals Stock (NASDAQ:SCPH)

Key Stats

Today's Range
$4.38
$4.57
50-Day Range
$2.24
$4.47
52-Week Range
$1.94
$5.65
Volume
336,245 shs
Average Volume
376,714 shs
Market Capitalization
$231.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

scPharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

SCPH MarketRank™: 

scPharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 193rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    scPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    scPharmaceuticals has received no research coverage in the past 90 days.

  • Read more about scPharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of scPharmaceuticals is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of scPharmaceuticals is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    scPharmaceuticals has a P/B Ratio of 16.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about scPharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    3.04% of the float of scPharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    scPharmaceuticals has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in scPharmaceuticals has recently decreased by 16.39%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    scPharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    scPharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.04% of the float of scPharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    scPharmaceuticals has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in scPharmaceuticals has recently decreased by 16.39%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    scPharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for scPharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for SCPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.78% of the stock of scPharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about scPharmaceuticals' insider trading history.
Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCPH Stock News Headlines

Utah’s New Oil Find
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
Q1 2025 scPharmaceuticals Inc Earnings Call
See More Headlines

SCPH Stock Analysis - Frequently Asked Questions

scPharmaceuticals' stock was trading at $3.54 at the beginning of 2025. Since then, SCPH shares have increased by 23.7% and is now trading at $4.38.

scPharmaceuticals, Inc. (NASDAQ:SCPH) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. The firm earned $11.75 million during the quarter, compared to analysts' expectations of $11.63 million. scPharmaceuticals had a negative net margin of 216.24% and a negative trailing twelve-month return on equity of 594.07%.
Read the conference call transcript
.

scPharmaceuticals (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
5/14/2025
Today
7/12/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCPH
CIK
1604950
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$12.00
Potential Upside/Downside
+219.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$85.15 million
Net Margins
-216.24%
Pretax Margin
-216.24%
Return on Equity
-594.07%
Return on Assets
-73.54%

Debt

Debt-to-Equity Ratio
3.86
Current Ratio
5.48
Quick Ratio
4.61

Sales & Book Value

Annual Sales
$36.33 million
Price / Sales
6.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.27 per share
Price / Book
16.22

Miscellaneous

Outstanding Shares
52,790,000
Free Float
50,269,000
Market Cap
$231.22 million
Optionable
Optionable
Beta
0.38
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:SCPH) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners